Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • Vascular Malformations (Apr 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Latency and viral persistence in HIV-1 infection
Janet D. Siliciano, Robert F. Siliciano
Janet D. Siliciano, Robert F. Siliciano
Published October 1, 2000
Citation Information: J Clin Invest. 2000;106(7):823-825. https://doi.org/10.1172/JCI11246.
View: Text | PDF
Commentary Article has an altmetric score of 4

Latency and viral persistence in HIV-1 infection

  • Text
  • PDF
Abstract

Authors

Janet D. Siliciano, Robert F. Siliciano

×

Figure 1

Options: View larger image (or click on image) Download as PowerPoint
Hypothetical decay curves showing plasma virus levels in patients starti...
Hypothetical decay curves showing plasma virus levels in patients starting and stopping HAART. (a) Biphasic decay curve of plasma HIV-1 RNA levels following initiation of HAART (1). Values below the limit of detection (20 copies/ml) are extrapolated and/or hypothetical. If HAART completely stopped ongoing viral replication, and if there were no stable reservoirs, eradication would be possible since the second phase of decay extrapolates to <1 residual infected cell in 2–3 years. (b) Decay curve showing additional effect of the latent reservoir in resting CD4+ T cells. If HAART stopped all residual viral replication, plasma viremia would decrease to the point where the only virus entering the plasma would be that derived from the occasional activation of latently infected resting CD4+ T cells. The decay rate of this latent reservoir is slow, with a half-life of at least 6 months in patients who have optimal suppression of viral replication on HAART (12, 17) and as long as 44 months in most patients on HAART (10). (c) Viral decay curve expected in most patients on HAART. Virus production continues at a level below the limit of detection of current ultrasensitive assays. Many patients have occasional “blips” of viremia that reach into the detectable range. In these patients, the latent reservoir persists with an extremely long half-life (44 months). (d) Effect of treatment interruption. A rapid rebound is expected due to the fact that most patients have continued virus production while on HAART. Viruses that are produced at the time HAART is stopped will replicate rapidly. (e) Effect of treatment interruption in patients who have no residual viral replication on HAART. A rebound is still expected due to activation of cells in the latent reservoir.

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts

Posted by 1 X users
Referenced in 2 patents
32 readers on Mendeley
See more details